Theranos cuts 155 jobs in second round of layoffs

Elizabeth Holmes
Theranos cut 340 jobs in October and is now eliminating 155 positions, leaving just 220.

Theranos is at it again: The embattled blood-testing startup is slashing 155 jobs, leaving just 220 to work on its tabletop diagnostic testing device. The layoffs come three months after the company dumped its questionable blood testing tech in favor of its new miniLab device.

The company has “identified a core team” of 220 employees who will advance the miniLab with eyes on commercialization, according to a statement. The 155 eliminated positions account for about 41% of Theranos’ workforce.

Theranos first unveiled the miniLab at the annual meeting of the American Association for Clinical Chemistry in August. The device is designed to process small blood samples in a “decentralized setting.” In October, Theranos officially abandoned its fingerprick blood testing tech, closing its clinical labs and Theranos Wellness Centers in California, Arizona and Pennsylvania. At the time, the company cut 340 employees, or 40% of its 790-person workforce.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

When Theranos debuted the miniLab, experts had been expecting an explanation of the technology behind the company’s fingerprick blood tests, which were first called into question by The Wall Street Journal in 2015. Over the ensuing year, Theranos’ chief operating officer jumped ship, the Centers for Medicare and Medicaid services has investigated the company’s Newark, CA, lab and handed down sanctions and its partner and main technology validator, Walgreens, has terminated their relationship and sued for breach of contract.

The CMS sanctions include revoking the Newark lab's CLIA certificate and banning Holmes from owning, operating or directing a lab for two years. While Theranos is appealing the sanctions, a sample-processing device that can be used outside a lab would be a way for the company to regain its feet after the firestorm surrounding the viability and accuracy of the fingerprick tests on which it was founded.


Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.